ArticleJournal of the American Heart Association2026
Sushi, von Willebrand Factor Type A, EGF and Pentraxin Domain-Containing Protein 1: A Novel Fibroblast-Derived Circulating Biomarker Reflecting Cardiac Fibrosis.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac fibrosis is a hallmark of heart failure and can be quantified by the extracellular volume fraction (ECV) derived from diagnostic imaging. However, noninvasive assessment is limited by the lack of specific circulating biomarkers. Recent large plasma proteome analyses have identified SVEP1 (Sushi, von Willebrand factor type A, EGF, and pentraxin domain containing 1) as candidate molecules reflecting cardiac fibrosis. This study aimed to evaluate SVEP1 as a biomarker for cardiac fibrosis.
methodsIn 72 patients with heart failure due to aortic stenosis, computed tomography-based ECV, serum SVEP1, and BNP (brain natriuretic peptide) levels were assessed. Multivariable regression was used to determine independent predictors of ECV. Publicly available single-nucleus RNA sequencing of human hearts revealed the cellular origin of
resultsSerum SVEP1 correlated with ECV and outperformed BNP in detecting fibrosis. Multivariable analysis revealed SVEP1 as an independent predictor of ECV. In addition, snRNA-seq revealed fibroblast-specific expression, expanded in failing hearts consistent with activated fibroblast emergence. Furthermore, TGF-β increased SVEP1 secretion in human cardiac fibroblasts, whereas its knockdown reduced SVEP1 secretion. Plasma Svep1 and cardiac hydroxyproline levels were elevated and positively correlated in mice.
conclusionsCompared with BNP, SVEP1, derived from cardiac fibroblasts, is more strongly associated with ECV-defined fibrosis and may serve as a novel fibrosis-specific circulating biomarker in heart failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.